BridgeMD
A study on the long-term efficacy, safety and persistence of immune response of a vaccine against Herpes Zoster in older adults.
EU CTIS ID: 2023-505255-51-00
What this study is testing
To evaluate the VE of HZ/su in preventing HZ.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants, who, in the opinion of the investigator, can and are willing to comply with the requirements of the protocol (e.g. completion of the HZ-specific diary cards/QoL questionnaires, return for follow-up visits and ability to have scheduled contacts to allow evaluation during the study) or participants with a caregiver who, in the opinion of the investigator, can and will comply with the requirements of the protocol (e.g., completion of the HZ-specific diary cards, availability for follow-up contacts).
- Written or witnessed/thumb printed informed consent obtained from the participant prior to performance of any study specific procedure.
- Medically stable participants as established by medical history and clinical examination before entering into the study.
- Participants who completed ZOSTER-049 study (following at least 1 dose of HZ/su in ZOSTER-006/022 studies).
You likely can't join if
- Any clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.
- Use of any investigational or non-registered product (drug, vaccine or medical device) for the treatment of HZ or VZV infection at the time of enrolment or their planned use during the study period.
- Previous vaccination against VZV or HZ and/or planned administration during the study of a VZV or HZ vaccine (including an investigational or non-registered vaccine other than HZ/su administered in studies ZOSTER-006/022 or ZOSTER- 049).
- Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device) for the prevention and/or treatment of HZ or VZV and which may have a possible activity against VZV.
The study team makes the final eligibility decision.
Where it's taking place
- Mexico
- Taiwan
- Korea, Republic of
- United States
- Hong Kong
- Canada
- Brazil
- United Kingdom
- Japan
- Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mexico; Taiwan; Korea, Republic of; United States; Hong Kong; Canada and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.